Kevin Gilbert, MD
Internal Medicine · West Palm Beach, FLNPI 1871558742
Payments from drug & device makers
Across 180 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$798
- AbbVie$449
- Abbott$408
- Novo Nordisk$329
- AstraZeneca$275
- GSK$225
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,572100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 46 | $798 |
| AbbVie(2 entities) | 29 | $449 |
| Abbott | 8 | $408 |
| Novo Nordisk | 18 | $329 |
| AstraZeneca | 17 | $275 |
| GSK | 12 | $225 |
| Pfizer | 8 | $174 |
| Amarin Pharma, Inc. | 9 | $174 |
| Novartis | 2 | $123 |
| Sanofi-aventis U.S. LLC | 5 | $105 |
| Amgen | 4 | $71 |
| Exact Sciences | 3 | $70 |
| Johnson & Johnson | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Bayer | 1 | $28 |
| Lundbeck LLC | 1 | $25 |
| Antares Pharma, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Gilead | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$163
- CARDIOMEMS$110
- ENTRESTO$100
How this compares
$3,572 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 146 | $154,789 |
| EliquisApixaban | 171 | $144,287 |
| OzempicSemaglutide | 91 | $111,873 |
| JardianceEmpagliflozin | 71 | $68,791 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $51,756 |
| Tresiba Flextouch U-100Insulin Degludec | 52 | $39,421 |
| XareltoRivaroxaban | 29 | $38,757 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $36,446 |
| TrulicityDulaglutide | 23 | $29,596 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $16,736 |
| LantusInsulin Glargine,hum.Rec.Anlog | 77 | $14,421 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $12,648 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $11,585 |
| EntrestoSacubitril/Valsartan | 13 | $10,011 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $7,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $798 | $184,386169 claims |
| PfizerEliquis | $174 | $144,287171 claims |
| Novo NordiskOzempic | $329 | $111,87391 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $225 | $53,18282 claims |
| GileadGenvoya | $18 | $51,75613 claims |
| Johnson & JohnsonXarelto | $43 | $38,75729 claims |
| Sanofi-aventis U.S. LLCLantus | $105 | $14,42177 claims |
| NovartisEntresto | $123 | $10,01113 claims |
| AbbVieSynthroid, Lumigan | $449 | $8,15583 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $4,655426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in West Palm Beach
- Mira BaronWest Palm Beach$29.6M
- Rafael NunezWest Palm Beach$4.6M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.